Veongen Therapeutics Gmbh

This is an early safety study testing a new gene therapy called VG801 for people with Stargardt disease, an inherited condition that causes vision loss. The trial will enroll 15 participants, aged 6 and older, who have specific genetic mutations. Doctors will inject the experimen…